<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173080</url>
  </required_header>
  <id_info>
    <org_study_id>14-003832</org_study_id>
    <nct_id>NCT02173080</nct_id>
  </id_info>
  <brief_title>Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).</brief_title>
  <official_title>Development and Assessment of the Psychometric Properties of a Polycystic Liver Disease-specific Patient Reported Outcomes Questionnaire (PLD-Q).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Pilot study will enable development &amp; assessment of a Polycystic Liver Disease-specific&#xD;
      patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is&#xD;
      characterized by the formation of numerous cysts in the liver, and can lead to severe&#xD;
      symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver&#xD;
      disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As liver function is preserved, quality of life is the main outcome in PLD. Patient reported&#xD;
      outcomes are increasingly utilized to assess treatment efficacy &amp; can include any endpoint&#xD;
      derived from patient reports &amp; are usually assessed by questionnaire. Several existing&#xD;
      generic questionnaires assess gastrointestinal symptoms, but include irrelevant items for&#xD;
      polycystic liver disease (PLD) &amp; do not examine relevant extra-abdominal symptoms. Also, a&#xD;
      questionnaire that assesses the full range of PLD related problems is more likely to be&#xD;
      responsive to changes after treatment initiation. Therefore, a tool that accurately detects&#xD;
      changes in PLD symptoms is required.&#xD;
&#xD;
      The development and first steps of validation of this questionnaire are already completed in&#xD;
      Netherlands. We will further develop this questionnaire for English speaking patients and&#xD;
      validate it in Mayo Clinic cohorts.&#xD;
&#xD;
      The study contains three phases. Phase 1: pilot testing of the directly translated&#xD;
      questionnaire (from dutch into english) in a small group of polycystic liver disease (PLD)&#xD;
      patients. We will include both symptomatic &amp; asymptomatic patients (i.e. from mild to severe&#xD;
      PLD). Phase 2: further refinement of the questionnaire using the results of the pilot test&#xD;
      and input of Mayo patient and clinician focus groups. Phase 3: Further validation in a large&#xD;
      cohort of 200 PLD patients with (1) comparison with 200 controls without PLD, (2)&#xD;
      cross-sectional correlation with total liver (TLV) &amp; kidney volumes (TKV), (3) comparing&#xD;
      ADPKD patients with &amp; without PLD (5) against other validated questionnaires (e.g. SF36) &amp;&#xD;
      (5) development of a custom &quot;Worry Questionnaire&quot; examining disease-related worries &amp;&#xD;
      concerns. Finally, longitudinal analyses will be performed to assess PLD-Q sensitivity to&#xD;
      change in symptoms. Statistical &amp; psychometric analyses will be provided by Mayo Clinic&#xD;
      quality of life Research group, &amp; developed in accordance with Food and Drug Administration&#xD;
      (FDA) guidance on patient-reported outcome measures in consultation with their Study&#xD;
      Endpoints &amp; Labeling Development Division.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>total score on the PLD-Q</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Short Form (36) Health Survey (SF36)</measure>
    <time_frame>baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality of life questionnaire (EORTC-QLQ-C30) symptom subscale</measure>
    <time_frame>baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol group 5 dimensions questionnaire visual analog score (EQ5D-VAS)</measure>
    <time_frame>baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total liver volume</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total kidney volume</measure>
    <time_frame>baseline</time_frame>
    <description>measured in patients with autosomal dominant polycystic kidney disease (ADPKD)</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">544</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Polycystic liver disease patients</arm_group_label>
    <description>will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADPKD group without PLD</arm_group_label>
    <description>will receive PLD-Q</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>receive PLD-Q</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLD patient focus group</arm_group_label>
    <description>to discuss and improve PLD-Q</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLD clinical expert focus group</arm_group_label>
    <description>to discuss and improve PLD-Q</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLD-Q</intervention_name>
    <description>polycystic liver disease questionnaire</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Polycystic liver disease patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with polycystic liver disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients â‰¥ 18 year&#xD;
&#xD;
          -  Polycystic liver, defined by &gt; 20 liver cysts on imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to speak or read the English properly&#xD;
&#xD;
          -  History of kidney or liver transplantation&#xD;
&#xD;
          -  Dialysis&#xD;
&#xD;
          -  Current use of experimental drugs (e.g. lanreotide, octreotide)&#xD;
&#xD;
          -  Recent liver resection or major surgery&#xD;
&#xD;
          -  Other comorbidities that can affect the outcome of the questionnaire, as deemed by the&#xD;
             investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie C Hogan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie C Hogan, MD, PhD</last_name>
    <phone>507-266-1963</phone>
    <email>Hogan.marie@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie C Hogan</last_name>
      <phone>507-266-1963</phone>
      <email>hogan.marie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Marie C Hogan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Gevers</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Kamath</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Sloan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joost Drenth</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Marie Hogan</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>autosomal dominant polycystic liver disease</keyword>
  <keyword>autosomal dominant polycystic kidney disease</keyword>
  <keyword>quality of life</keyword>
  <keyword>patient reported outcome tool</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

